Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of GSK's AL-101?
AL-101 is a monoclonal antibody commercialized by GSK, with a leading Phase II program in Alzheimer's Disease;Mild Cognitive Impairment;Dementia Associated...
AL-101 by Alector for Alzheimer's Disease: Likelihood of Approval
AL-101 is under clinical development by Alector and currently in Phase II for Alzheimer's Disease. According to GlobalData, Phase II...
AL-101 by Alector for Mild Cognitive Impairment: Likelihood of Approval
AL-101 is under clinical development by Alector and currently in Phase II for Mild Cognitive Impairment. According to GlobalData, Phase...
AL-101 by Alector for Dementia Associated With Alzheimer's Disease: Likelihood of Approval
AL-101 is under clinical development by Alector and currently in Phase II for Dementia Associated With Alzheimer's Disease. According to...